The Pharma Data
OCTOBER 16, 2020
As pharma companies search for solutions to avoid cancelling or delaying clinical trials, virtualizing trials are fast becoming commonplace during the Covid-19 pandemic. In vitro antiviral technology proves effective against SARS-CoV-2 in human airway infection model.
pharmaphorum
DECEMBER 1, 2022
Exploring the implementation of complex in-vitro models for drug development. The pharmaceutical industry globally is realising the growing potential of in vitro tissue models for drug discovery, pathology modelling and validation, safety and toxicity. Billion by 2028. Billion by 2028. Event Hashtag: #3DCellCulture2023.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
JANUARY 18, 2022
Developing Complex, Translatable and Physiologically-Relevant Cellular Models in vitro. Key Benefits of Attending: • Discuss the uses of advanced cell technologies to construct in vitro models of human tissues. Uncover the major benefits of 3D modelling in enhancing clinical translation and predictability. Who Should Attend?
pharmaphorum
FEBRUARY 13, 2022
Quris’ BioAI safety prediction platform – which is based on human tissue samples on chips, nanosensors and machine learning – will be compared to traditional in vitro and in vivo laboratory techniques for spotting toxicity. The post Merck will assess Quris’ AI ‘patient-on-a-chip’ drug safety appeared first on.
pharmaphorum
OCTOBER 12, 2020
Over the past few years, 3D Cell Culture has gained momentum within the pharmaceutical industry due to the benefits that this model offers for in vitro applications patient-derived tissues, drug discovery, predictivity and validation, and safety and toxicity. 3D-cellculture.com/PR1. . 3D-cellculture.com/PR1. 3D Cell Culture 2020.
pharmaphorum
JULY 6, 2022
A Franco-German joint venture company – Aurobac Therapeutics – has been formed to try to tackle the rising threat of antimicrobial resistant (AMR) infections. It’s the latest in a series of actions taken by the drug industry to try to reverse the mass exodus of companies from antimicrobials R&D over the last few decades.
Drug Discovery World
AUGUST 22, 2023
Originator pharma companies are developing ever more complex products, which are transforming the medical landscape, but their cost places an increasing burden on healthcare budgets worldwide. In the meantime, the absence of generics is costing payors and patients billions of dollars in unnecessary additional healthcare expenditure.
Expert insights. Personalized for you.
52 
Let's personalize your content